Integrated BioPharma Short Interest Ratio and Short Volume

-0.02 (-1.82 %)
(As of 09/17/2021 10:53 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,200 shs
Average Volume17,079 shs
Market Capitalization$32.21 million
P/E Ratio4.32
Dividend YieldN/A

Integrated BioPharma (OTCMKTS:INBP) Short Interest Data

Current Short Volume300 shares
Previous Short Volume3,100 shares
Change Vs. Previous Month-90.32%
Dollar Volume Sold Short$282.00
Short Interest Ratio / Days to Cover0.0
Last Record DateAugust, 31 2021
Outstanding Shares29,820,000 shares
Percentage of Shares Shorted0.00%
Today's Trading Volume1,200 shares
Average Trading Volume17,079 shares
Today's Volume Vs. Average-92.97%

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Integrated BioPharma ?

Sign up to receive the latest short interest report for Integrated BioPharma and its competitors with MarketBeat's FREE newsletter.

Integrated BioPharma (OTCMKTS:INBP) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/31/2021300 shares $282.00 -90.3%N/A0 $0.94
8/13/20213,100 shares $2,974.45 +3,000.0%N/A0.1 $0.96
7/30/2021100 shares $104.00 -94.4%N/A0 $1.04
7/15/20211,800 shares $1,931.40 +50.0%N/A0.1 $1.07
6/30/20211,200 shares $1,320.00 -67.6%N/A0 $1.10
6/15/20213,700 shares $4,366.00 +516.7%N/A0.1 $1.18
5/28/2021600 shares $732.00 +500.0%N/A0 $1.22
5/14/2021100 shares $118.00 -75.0%N/A0 $1.18
4/30/2021400 shares $420.00 +100.0%N/A0 $1.05
4/15/2021200 shares $218.00 +100.0%N/A0 $1.09
3/31/2021100 shares $105.00 -91.7%N/A0 $1.05
3/15/20211,200 shares $1,152.00 -14.3%N/A0.1 $0.96
2/26/20211,400 shares $1,358.00 -70.8%N/A0 $0.97
2/12/20214,800 shares $4,608.00 -57.1%N/A0.1 $0.96
1/29/202111,200 shares $10,416.00 +1,020.0%N/A0.4 $0.93
1/15/202111,200 shares $9,072.00 +64.7%N/A0.8 $0.81
12/31/20202,500 shares $1,762.50 -77.7%N/A0.1 $0.71
12/15/202011,200 shares $8,904.00 +64.7%N/A0.8 $0.80
11/30/20206,800 shares $5,508.00 +3,300.0%N/A0.1 $0.81
11/15/2020200 shares $120.00 No ChangeN/A0.1 $0.60
9/30/2020200 shares $94.00 +100.0%N/A0 $0.47
9/15/2020100 shares $44.00 No ChangeN/A0 $0.44
8/31/2020100 shares $42.00 No ChangeN/A0 $0.42
8/14/2020100 shares $42.00 No ChangeN/A0.1 $0.42
7/15/20204,500 shares $2,128.50 +4,400.0%N/A1 $0.47

Integrated BioPharma (OTCMKTS:INBP) Short Interest FAQ

speech bubbles
speech bubbles

What is Integrated BioPharma's current short interest?

Short interest is the volume of Integrated BioPharma shares that have been sold short but have not yet been closed out or covered. As of August 31st, investors have sold 300 shares of INBP short. Learn More on Integrated BioPharma's current short interest.

Is Integrated BioPharma's short interest increasing or decreasing?

Integrated BioPharma saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 300 shares, a decline of 90.3% from the previous total of 3,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Integrated BioPharma's short interest compare to its competitors?

0.00% of Integrated BioPharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Integrated BioPharma: Purple Biotech Ltd. (0.00%), NeuBase Therapeutics, Inc. (0.00%), Corbus Pharmaceuticals Holdings, Inc. (5.97%), BioLineRx Ltd. (0.00%), Longboard Pharmaceuticals, Inc. (0.97%), Eton Pharmaceuticals, Inc. (6.91%), Daré Bioscience, Inc. (0.00%), Orgenesis Inc. (2.76%), Exicure, Inc. (5.15%), and Processa Pharmaceuticals, Inc. (2.23%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Square, Inc. ($9.81 billion), S&P Global Inc. ($7.52 billion), Advanced Micro Devices, Inc. ($7.18 billion), Charter Communications, Inc. ($6.21 billion), Wayfair Inc. ($4.60 billion), Zoom Video Communications, Inc. ($3.23 billion), Uber Technologies, Inc. ($3.11 billion), Palo Alto Networks, Inc. ($2.74 billion), Teladoc Health, Inc. ($2.52 billion), and Etsy, Inc. ($2.16 billion). View all of the most shorted stocks.

What does it mean to sell short Integrated BioPharma stock?

Short selling INBP is an investing strategy that aims to generate trading profit from Integrated BioPharma as its price is falling. Integrated BioPharma's stock is trading down $0.02 today. To short Integrated BioPharma stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Integrated BioPharma will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Integrated BioPharma?

A short squeeze for Integrated BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of INBP, which in turn drives the price of the stock up even further.

How often is Integrated BioPharma's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INBP, twice per month. The most recent reporting period available is August, 31 2021.

This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.